Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.73
-0.17 (-2.80%)
Jun 5, 2026, 11:34 AM EDT - Market open

Taysha Gene Therapies Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Taysha Gene Therapies stock has a consensus rating of "Strong Buy" and an average price target of $12.23. The average 1-year stock price forecast is 113.62% higher than the current stock price, while the lowest is $8.00 (+39.74%) and the highest is $19 (+231.88%).

Price Target: $12.23 (+113.62%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$8.00$12.23$12$19
Change+39.74%+113.62%+109.61%+231.88%

Analyst Ratings

The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy111111111110
Buy333333
Hold000000
Sell000000
Strong Sell000000
Total141414141413

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
BMO Capital
BMO Capital
Buy
Reiterates
$10
BuyReiterates$10+74.67%May 22, 2026
Unknown Analyst
Bank of America Securities
No rating
Bank of America Securities
Buy
Reiterates
$9
BuyReiterates$9+57.21%May 8, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$17
BuyMaintains$17+196.94%May 7, 2026
Unknown Analyst
Wells Fargo
No rating
Wells Fargo
Buy
Maintains
$11
BuyMaintains$11+92.14%May 7, 2026
Chardan Capital
Chardan Capital
Buy
Reiterates
$12
BuyReiterates$12+109.61%May 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.85M
from 9.77M
Decreased by -81.11%
Revenue Next Year
29.77M
from 1.85M
Increased by 1,512.64%
EPS This Year
-0.44
from -0.32
EPS Next Year
-0.44
from -0.44
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-2.50M15.45M8.33M9.77M1.85M
Revenue Growth
--517.55%-46.07%17.28%-81.11%
Gross Profit
-2.50M15.45M8.33M9.77M1.38M
Gross Margin
-100.00%100.00%100.00%100.00%75.00%
Operating Income
-173.27M-126.03M-71.37M-86.62M-110.50M-177.48M
Net Income
-174.52M-166.01M-111.57M-89.30M-109.00M-172.04M
EPS
-----0.32-0.44
Free Cash Flow
-71.32M-75.31M-68.51M-48.15M-56.70M-155.31M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High15.0M
Avg1.8M
Lown/a

Revenue Growth

Revenue Growth202620272028
High
53.5%
Avg
-81.1%
Low
-100.0%

EPS Forecast

EPS202620272028
High-
Avg-0.44
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-